References
- Speroff L. The perimenopause: definitions, demography, and physiology. Obstet Gynecol Clin North Am 2002;29:397–410
- FSRH Guideline Contraception for Women Aged Over 40 Years. (Updated November 2017). https://www.fsrh.org/standards-and-guidance/documents/fsrh-guidance-contraception-for-women-aged-over-40-years-2017/ Accessed 10.08.2018
- Faculty of Sexual & Reproductive Healthcare (FSRH). Contraception for Women Over 40 Years. 2010. http://www.fsrh.org/standards-and-guidance/documents/cec-ceu-guidance-womenover40-jul-2010/ Accessed 12.8.2018
- Antinori S, Gholami GH, Versaci C, et al. Obstetric and prenatal outcome in menopausal women: a 12-year clinical study. Reprod Biomed Online 2003;6:257–61
- National Institute for Health and Care Excellence (NICE). Menopause: Full Guideline. 2015. https://www.nice.org.uk/guidance/ng23/evidence/full-guideline-559549261accessed 12.08.2018
- Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007;44:62–9
- NIH Osteoporosis and Related Bone Diseases National Resource Center. Osteoporosis Overview 2015; https://www.niams.nih.gov/Health_Info/Bone/Osteoporosis/overview.pdf
- Bitzer J, Platano G, Tschudin S, et al. Sexual counseling in elderly couples. J Sex Med 2008;5:2027–43
- Miller TA, Allen RA, Kaunitz AM, et al. Contraception for midlife women: a review. Menopause 2018;25:817–27
- World Health Organization. Family planning: a global handbook for providers. Available at: http://apps.who.int/iris/bitstream/10665/44028/1/9780978856373_eng.pdf. Accessed September 12, 2017
- Black A, Guilbert E, Costescu D, et al. Canadian Contraception Consensus (Part 1 of 4)). J Obstet Gynaecol Can 2015;37:936–42
- Faculty of Sexual and Reproductive Healthcare Clinical Guidance. Intrauterine Contraception. April 2015 (updated June 2015) ISSN 1755-103X
- FSRH Faculty of Sexual & Reproductive Healthcare (FSRH). UK Medical Eligibility Criteria for Contraceptive Use (UKMEC). 2016. http://www.fsrh.org/standards-and-guidance/external/ukmec-2016-digital-version/ accessed 10.08. 2018
- Ashley SF, Gaudet MM, La Veccia C. Intrauterine devices and endometrial cancer risk: a pooled analysis of the epidemiology of endometrial cancer consortium. Int J Cancer 2015;136:E410–22
- Faculty of Sexual & Reproductive Healthcare (FSRH). Barrier Methods: Contraception and STI Prevention. 2012. http://www.fsrh.org/documents/ceuguidancebarriermethodscontraceptionsdi/ Accessed 12.08.2018
- World Health Organization. WHO/CONRAD Technical Consultation on Nonoxynol-9. 2003. http://apps.who.int/iris/bitstream/10665/68510/1/WHO_RHR_03.08.pdf. Accessed 13.08.2018
- Trussell J, Contraceptive efficacy. In: Hatcher R, Trussell J, Nelson A, et al. (eds.). Contraceptive Technology. New York, NY: Ardent Media, 2011
- Lidegaard O, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. Br Med J 2011;343:d6423
- Sugiura K, Kobayashi T, Ojima T. Risks of thromboembolism associated with hormonal contraceptives related to body mass index and aging in Japanese women. Thromb Res 2016;137:11–16
- Reid RL, Westhoff C, Mansour D, et al. Oral contraceptives and venous thromboembolism consensus opinion from an international workshop held in Berlin, Germany in December. J Fam Plann Reprod Health Care 2010;36:117–22
- Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012;366:2257–66
- Fruzzetti F, Tremollieres F, Bitzer J. An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest. Gynecol Endocrinol 2012;28:400–8
- Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 2016;94:328–39
- Ffprhc Guidance (J. Contraception for women aged over 40 years. J Fam Plan Reprod Health Care 2005;2005:3151–64
- Tuckey J. Combined oral contraception and cancer. Br J Fam Plann 2000;26:237–40
- Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713–27
- Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346:2025–32
- Marchbanks PA, Curtis KM, Mandel MG, et al. Oral contraceptive formulation and risk of breast cancer. Contraception 2012;85:342–50
- Mørch L, Skovlund C, Hannaford P, et al. Contemporary contraception and the risk of breast cancer. N Engl J Med 2017;377:2228–39
- Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003;361:1159–67
- Iversen L, Sivasubramaniam S, Lee AJ, et al. Lifetime cancer risk and combined oral contraceptives: the royal college of general practitioners’ Oral Contraception Study. Am J Obstet Gynecol 2017;216:580.e1–.e9
- Vessey M, Yeates D. Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study. Contraception 2013;88:678–83
- Cancer Research UK. Cervical Cancer In Situ (D06): 2012–2014. 2016 http://www.cancerresearchuk.org/sites/default/files/cstream-node/cases_crude_cervixsit_I14.pdf
- ACOG Frequently asked questions, March 2018. www.acog.org/Clinical-Guidance-and-Publications/Patient-Education-FAQs-List
- Gallo MF, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2003;2:CD003987
- Hannaford PC, Iversen L, Macfarlane TV, et al. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ 2010;340:c927
- Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol 2013;122:139–47
- Weiderpass E, Adami H, Baron JA, Magnusson C, et al. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999;10:277–84
- Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 2013;22:1931–43
- Fernandez E, Vecchia CL, Balducci A, et al. Oral contraceptives and colorectal cancer risk: a metaanalysis. Br J Cancer 2001;84:722–7
- Burkman RT, Collins JA, Shulman LP, et al. Current perspectives on oral contraceptive use. Am J Obstet Gynecol 2001;185:4–12
- Chapurlat RD, Garnero P, Sornay-Rendu E, et al. Longitudinal study of bone loss in pre- and perimenopausal women: evidence for bone loss in perimenopausal women. Osteoporos Int 2000;11:493–8
- Kuohung W, Borgatta L, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception 2000;61:77–82
- Berenson AB, Radecki RM, Grady JJ, et al. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Am J Obstet Gynecol 2001;98:576–82
- Iyer V, Farquhar C, Jepson R. Oral contraceptive pills for heavy menstrual bleeding. Cochrane Database Syst Rev 2000;2:CD000154
- Fraser I, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol 1991;31:66–70
- Wasiak R, Filonenko A, Vanness DJ, et al. Impact of estradiol-valerate/dienogest on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding. Int J Womens Health 2012;4:271–8
- Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhea. Cochrane Database Syst Rev 2001;4:CD002120
- Hendrix SL, Alexander NJ. Primary dysmenorrhoea treatment with a desogestrel-containing low dose oral contraceptive. Contraception 2002;66:393–9
- Moore J, Kennedy S, Prentice A. Modern approach to combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2000;2:CD001019
- Kaunitz AM. Oral contraceptive use in perimenopause. Am J Obstet Gynecol 2001;185:S32–S7
- Holt VL, Daling JR, McKnight B, Moore D, Stergachis A, Weiss NS. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obstet Gynecol 1992;79:529–33
- Westhoff C, Britton JA, Gammon MD, Wright T, Kelsey JL. Oral contraceptive and benign ovarian tumors. Am J Epidemiol 2000;152:242–6
- Ezeh U, Huang A, Landay M, Azziz R. Long-term response of hirsutism and other hyperandrogenic symptoms to combination therapy in polycystic ovary syndrome. J Womens Health (Larchmt) 2018;27:892–902
- Bitzer J, Römer T. Lopes da Silva Filho A. The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review. Eur J Contracept Reprod Health Care 2017;22:172–82
- Spector TD, Hochberg MC. The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis. J Clin Epidemiol 1990;43:1221–30
- Kingsberg SA, Althof S, Simon JA, et al. Female sexual dysfunction-medical and psychological treatments, Committee 14. J Sex Med 2017;14:1463–91
- Lopez LM, Kaptein A, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2008;CD006586
- World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. Contraception 1998;57:315–24
- American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 121: Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol 2011;118:184–96
- Chakhtoura Z, Canonico M, Gompel A, et al. Progestogen-only contraceptives and the risk of stroke: a meta-analysis. Stroke 2009;40:1059–62
- Chakhtoura Z, Canonico M, Gompel A, Scarabin PY, Plu-Bureau G. Progestogen-only contraceptives and the risk of acute myocardial infarction: a meta-analysis. J Clin Endocrinol Metab 2011;96:1169–74
- Shapiro S, Rosenberg L, Hoffman M, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 2000;151:396–403
- The ESHRE Capri Workshop Group. Hormonal contraception without estrogens. Hum Reprod Update 2003;9:373–86
- Backman T, Rauramo I, Jaakkola K, et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 2005;106:813–17
- Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 2011;83:211–17
- Soini T, Hurskainen R, Grenman S, Maenpaa J, Paavonen J, Pukkala E. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol 2014;124:292–9
- Soini T, Hurskainen R, Grenman S, et al. Levonorgestrel-releasing intrauterine system and the risk of breast cancer: a nationwide cohort study. Acta Oncol 2016;55:188–92
- Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep 2016;65:1–66
- Kaunitz AM, Peipert JF, Grimes DA. Injectable contraception: issues and opportunities. Contraception 2014; 89:331–4
- Kaunitz AM. Injectable contraception. New and existing options. Obstet Gynecol Clin North Am 2000;27:741–80
- Skovlund CW, Mørch LS, Kessing LV, et al. Association of hormonal contraception with depression. JAMA Psychiatry 2016;73:1154–62
- Bitzer J. Hormonal contraception and depression: another pill scandal? Eur J Contracept Reprod Health Care 2017;22:1–2
- Merki-Feld GS, Apter D, Bartfai G, et al. ESC expert statement on the effects on mood of the natural cycle and progestin-only contraceptives. Eur J Contracept Reprod Health Care 2017;22:247–9
- Depot medroxyprogesterone acetate (DMPA) and the risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991;49:186–90
- Sangi-Haghpeykar H, Poindexter AN, Bateman L, et al. Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol 1996;88:227–33
- Schering Health Care Ltd. Mirena. 0053/0265, 1-8. 2002. http://www.medicines.org.uk. Accessed 09.08.2018
- Hildago M, Bahamondes L, Perrotti M, et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002;65:129–32
- NICE clinical guideline 44, Developed by the National Collaborating Centre for Women’s and Children’s Health. Heavy Menstrual Bleeding. https://www.nice.org.uk/guidance/ng88 [accessed 15 July 2018]
- World Health Organization. Medical Eligibility Criteria (Fifth Edition) 2015. http://www.who.int/reproductivehealth/publications/family_planning/MEC-5/en/
- Bitzer J, Marin V, Lira J. Contraceptive counselling and care: a personalized interactive approach. Eur J Contracept Reprod Health Care 2017;22:418–23